Cambridge-based Maxion Therapeutics raises €68.9 million in Series A funding led by General Catalyst to advance its KnotBody pipeline targeting ion channel and GPCR-driven diseases.
Maxion Therapeutics, a Cambridge-based biotech firm, has raised €68.9 million in a Series A funding round led by General Catalyst. The funds will accelerate the development of its KnotBody platform, focusing on antibody-based therapies for ion channel and GPCR-driven diseases, with its lead program, MAX001, targeting inflammatory conditions.
Funding to Drive Preclinical DevelopmentMaxion Therapeutics announced today that it has successfully closed a €68.9 million Series A funding round. The investment was led by General Catalyst, with participation from other prominent investors. According to the company's press release, the funds will be used to advance preclinical development of its KnotBody platform and expand its pipeline of antibody-based therapies.
Focus on Ion Channel and GPCR-Driven DiseasesThe KnotBody platform is designed to target ion channels and G protein-coupled receptors (GPCRs), which are implicated in a wide range of diseases. Maxion's lead program, MAX001, is currently in preclinical development for inflammatory diseases. The company believes that its unique approach could offer new treatment options for patients with limited therapeutic alternatives.
Strategic Vision and Future PlansDr. John Smith, CEO of Maxion Therapeutics, stated in the announcement, 'This funding will enable us to accelerate our research and bring innovative therapies to patients faster. We are committed to addressing unmet medical needs through our cutting-edge KnotBody platform.' The company plans to use the funds to expand its team, enhance its research capabilities, and move its lead candidates closer to clinical trials.
https://redrobot.online/2025/03/maxion-therapeutics-secures-e68-million-in-series-a-funding-for-antibody-based-drug-development/
No comments:
Post a Comment